Sanofi-Aventis files revocation proceedings in UPC against Amgen’s Repatha® (evolocumab)

Jun 2, 2023

Sanofi-Aventis filed one of the earliest UPC revocation cases against Amgen’s Repatha® (evolocumab) patent EP3666797 in Munich on 2 June 2023, the day after the UPC’s commencement. Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).  To date, this is the only UPC case relating to a monoclonal antibody.

On 18 May 2023, the US Supreme Court invalidated genus claims in two Amgen patents relating to Repatha® (evolocumab).

Print Page Mail Article